Details for New Drug Application (NDA): 208749
The generic ingredient in LEVOTHYROXINE SODIUM is levothyroxine sodium. There is one drug master file entry for this compound. Fifty suppliers are listed for this compound. Additional details are available on the levothyroxine sodium profile page.
Summary for 208749
| Tradename: | LEVOTHYROXINE SODIUM |
| Applicant: | Maia Pharms Inc |
| Ingredient: | levothyroxine sodium |
| Patents: | 0 |
Suppliers and Packaging for NDA: 208749
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| LEVOTHYROXINE SODIUM | levothyroxine sodium | POWDER;INTRAVENOUS | 208749 | ANDA | Sagent Pharmaceuticals | 25021-468 | 25021-468-10 | 1 VIAL in 1 CARTON (25021-468-10) / 5 mL in 1 VIAL |
| LEVOTHYROXINE SODIUM | levothyroxine sodium | POWDER;INTRAVENOUS | 208749 | ANDA | Sagent Pharmaceuticals | 25021-469 | 25021-469-10 | 1 VIAL in 1 CARTON (25021-469-10) / 5 mL in 1 VIAL |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | POWDER;INTRAVENOUS | Strength | 100MCG/VIAL | ||||
| Approval Date: | Dec 21, 2018 | TE: | AP | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | POWDER;INTRAVENOUS | Strength | 200MCG/VIAL | ||||
| Approval Date: | Dec 21, 2018 | TE: | AP | RLD: | No | ||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | RX | Dosage: | POWDER;INTRAVENOUS | Strength | 500MCG/VIAL | ||||
| Approval Date: | Dec 21, 2018 | TE: | AP | RLD: | No | ||||
Complete Access Available with Subscription
